Tobias Dechow
Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2(nd) -line therapy for relapsed and refractory multiple myeloma - a phase II trial
Mey U, Ruefer A, Ziske C, Knauf W, Cathomas R, von Moos R, Hitz F, Sauter R, Hiendlmeyer E, Cantoni N, Bargetzi M, Fischer N, Doerfel S, Brugger W, Schwarb H, Pederiva S, Schwarzer A, Dechow T, Jehner P, Rauh J, Taverna C, Schmid M, Schmidt-Hieber M, Driessen C. Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2(nd) -line therapy for relapsed and refractory multiple myeloma - a phase II trial. Br J Haematol 2016
16.12.2016Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2(nd) -line therapy for relapsed and refractory multiple myeloma - a phase II trial
16.12.2016Br J Haematol 2016
Mey Ulrich J M, Ruefer Axel, Ziske Carsten, Knauf Wolfgang, Cathomas Richard, von Moos Roger, Hitz Felicitas, Sauter Rafael, Hiendlmeyer Elke, Cantoni Nathan, Bargetzi Mario, Fischer Natalie, Doerfel Steffen, Brugger Wolfram, Schwarb Heike, Pederiva Stefanie, Schwarzer Andreas, Dechow Tobias, Jehner Paul, Rauh Jacqueline, Taverna Christian J, Schmid Mathias, Schmidt-Hieber Martin, Driessen Christoph
Imaging proliferation to monitor early response of lymphoma to cytotoxic treatment
Graf N, Dechow T, Schwaiger M, Peschel C, zum Büschenfelde C, Senekowitsch-Schmidtke R, Wester H, Schuster T, Fend F, den Hollander J, Herrmann K, Buck A. Imaging proliferation to monitor early response of lymphoma to cytotoxic treatment. Mol Imaging Biol 2008; 10:349-55.
14.08.2008Imaging proliferation to monitor early response of lymphoma to cytotoxic treatment
14.08.2008Mol Imaging Biol 2008; 10:349-55
Graf Nicolas, Dechow Tobias, Schwaiger Markus, Peschel Christian, zum Büschenfelde Christian Meyer, Senekowitsch-Schmidtke Reingard, Wester Hans-Jürgen, Schuster Tibor, Fend Falko, den Hollander Jürgen, Herrmann Ken, Buck Andreas K